Skip to main content
OpenTrials
Completed

NCT Number: NCT03869216

Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men

This behavioral clinical trial assesses the efficacy of a educational intervention to increase shared decision making about prostate-specific antigen (PSA)-based screening for prostate cancer among African American males. Half of participants will receive a multimedia educational intervention, while the other half will receive usual care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–69 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Tulane Medical Center

New Orleans, Louisiana, 70112, United States

About this study

The 2018 U.S. Preventive Services Task Force (USPSTF) final recommendation states that male patients and their providers engage in a shared-decision making process about the benefits and harms of PSA-based screening. As characterized by the USPSTF, these conversations are particularly important for African American men given increased ambiguity due to the lack of PSA-based research specific to this population and increased risk of prostate cancer mortality attributed to late stage at diagnosis and more aggressive prostate cancer phenotypes seen in African American men.

The goal of this randomized behavioral clinical trial is to advance the translation path of implementing the decision-making process in clinical encounters by evaluating the efficacy of an educational intervention for African American males to increase shared decision making about PSA-screening versus usual care. The intervention will use multimedia educational training materials to increase understanding of prostate cancer, PSA-based screening, and shared decision making among patients and their primary care providers (PCPs).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Patient Inclusion Criteria:

  • Receiving care at the clinical sites
  • Identify as African American male
  • Ages 40-69 years old

Patient Exclusion Criteria:

  • Personal history of prostate cancer at the time of consent
  • Cognitive impairment that would interfere with participation in the study
  • Unable to complete any aspect of the intervention within the specified time limit

Treatment and study plan

Educational Shared Decision-Making Intervention

Behavioral

The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.

Primary outcomes

  1. Shared Decision-making

    Time frame: One month after audio-recorded visit

    The Observing Patient Involvement (OPTION) Scale was used for the coding of the SDM. The total OPTION scale ranges from 0 to 48. Higher values on the scale mean higher patient involvement in the decision-making process.

Secondary outcomes

  1. Quality of Decision (QD)

    Time frame: Up to 24 weeks after the audio-recorded visit

    The total QD score ranges from 0 to 100. Higher percentage scores mean higher quality of the decision made.

  2. Preference-Congruent Decision Making

    Time frame: Through study completion, an average of 1 year

    The Intention-to-Screen score ranges from 0 to 1. Score = 0 means no intention to receive the PSA test while score = 1 means intention to receive the PSA test.

    Preference-concordant decision making will be scored as 1 (POSITIVE) for those patients with Intention-to-Screen value = 1 who actually receive the PSA test during the study timeframe, or for those patients with Intention-to-Screen value = 0 who did not receive it.

    Preference-concordant decision making will be scored as 0 (NEGATIVE) for those patients with Intention-to-Screen value = 1 who did not receive the PSA test during the study timeframe, or for those patients with Intention-to-Screen value = 0 who did receive it.

    A congruence score of 1 means congruence between patient intention and real action, while a congruence score of 0 means patient in congruence between intention and real action.

Other outcomes

  1. Acceptability

    Time frame: Through study completion, an average of 1 year

    Participants complete a structured questionnaire to rate the acceptability of the enrollment process, study procedures, and their overall satisfaction with the study. The score ranges from 10 to 50. Higher scores mean higher acceptability of study procedures.

Sponsors and collaborators

Lead sponsor

Xavier University of Louisiana.

Other

Collaborators

  • National Institute on Minority Health and Health Disparities (NIMHD)
  • Tulane University

Registry information

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Mar 11, 2019
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.